Please ensure Javascript is enabled for purposes of website accessibility

These Are the Top 5 Stocks the Smart Money Is Selling

By Rich Duprey - Oct 2, 2017 at 7:33AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When the smart money exits a position, it should give you a noodle point about why they're selling.

When the smart money moves into a stock, investors may want to take notice, because it just might signal the start of an upswing in its value. Similarly, when the smart money withdraws its money from a holding, you may want to pay attention, because it may see problems others are missing.

The smart money can definitely be dumb sometimes, but it's probably never wise to dismiss its moves out of hand. Recently, personal-finance website WalletHub examined the most recent SEC disclosures filed by more than 400 hedge funds and found their funds were going in similar directions at the end of the second quarter of 2017.

Here are the top five stocks hedge funds were selling, which may help you gain insight into where they think the stock market is cooling off.

Pouring milk into a bowl of cereal

Image source: Getty Images.

1. Kellogg

Cereal maker Kellogg (K 0.62%) has been pressured first by the overall weakness in the food industry, but also by changing consumer preferences surrounding breakfast, changes that have been evident for several years now.

While cold cereal remains a popular favorite for most people in the morning, higher-protein foods such as yogurt and grab-and-go snacks have been gaining popularity. Kellogg is transitioning itself to keep pace with the new reality and recently noted that where cereal used to make up the lion's share of its business in 2000, today snacks account for half of sales.

2. Apple

Were hedge funds anticipating the seemingly tepid response to Apple's (AAPL 1.62%) new iPhone X? Where previous releases were greeted by long lines and people camping out overnight to get their hands on the latest iteration, the newest iPhone had none of that, with numerous reports of there being no lines and no wait. It could have something to do with the $1,000 price of the phone, which may have kept people away, but also as each new generation of iPhone comes online, the obsolescence of previous models decreases. Someone with an iPhone 8 (or even a 6) might not feel the need to upgrade right away, as that model is more than up to the task of meeting most users' needs.

Still, Apple also happened to be one of the top five stocks that other hedge funds were buying, perhaps in anticipation that the iPhone X would be a blowout.

Scientists looking at a specimen

Image source: Getty Images.

3. Eli Lilly

Early this year, drugmaker Eli Lilly (LLY 0.15%) was stunned when the FDA rejected the application it and partner Incyte submitted for baricitinib, a therapy for rheumatoid arthritis. While it was supposed to be a blockbuster drug for Lilly, it had to face the prospect of years of delays and new clinical trials. It's understandable why investors sold off the drugmaker.

But Eli Lilly subsequently surprised the market. It and Incyte were able to negotiate with the FDA to not have to perform new studies with the drug, and Eli Lilly said it could resubmit its application for consideration as early as January 2018. This could be a case where the smart money moved too quickly.

4. Johnson & Johnson

Consumer-products and pharmaceutical giant Johnson & Johnson (JNJ 1.13%) has been an exemplary stock for decades, delivering outsized returns for investors, but it could have been the acquisition of Swiss drug developer Actelion for $30 billion that soured hedge funds' outlook. While it would significantly bolster Johnson & Johnson's portfolio of prescription drugs, it also makes the company even more dependent on that arm of its business. With heightened risks from drug-pricing reform to therapies always moving off patent, and competitive pressures at a peak, the smart money may have decided it was a good time to leave.

Global stock chart rising

Image source: Getty Images.

5. JPMorgan Chase

The stocks of the biggest U.S. banks took hard hits early on in the year, as the prospects of lower revenue resulting from declining fixed income took a toll. Both JPMorgan Chase (JPM 1.28%) and Bank of America were hit hard in March, with shares of each falling about 10% on concern that second-quarter results would come under pressure.

Stock market activity had been fairly subdued, and without singular events to keep rolling the waters, such as Brexit or President Trump's election, the trading revenues the biggest banks generated was expected to drop. Perhaps the smart money should have been smarter to know that nothing remains in stasis forever, and after hitting a summer low, the stocks of both JPMorgan and Bank of America have jumped 15%.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$179.52 (1.13%) $2.01
Apple Inc. Stock Quote
Apple Inc.
AAPL
$138.93 (1.62%) $2.21
JPMorgan Chase & Co. Stock Quote
JPMorgan Chase & Co.
JPM
$114.05 (1.28%) $1.44
Kellogg Company Stock Quote
Kellogg Company
K
$71.78 (0.62%) $0.44
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$324.71 (0.15%) $0.48
Bank of America Corporation Stock Quote
Bank of America Corporation
BAC
$31.56 (1.38%) $0.43
Incyte Corporation Stock Quote
Incyte Corporation
INCY
$77.67 (2.24%) $1.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.